UK Home Office loosens restrictions on GW’s Epidyolex
The cannabinoid has been reclassified as a Schedule 5 medicine meaning that it can be dispensed more easily
Read More
Tag: GW Pharma
GW Pharma regains Sativex rights in UK
The company is taking the reins back from Bayer.
Read More
NHS fast-tracks access to Epidyolex for severe epilepsy
Doctors will be able to prescribe the drug from January 6
Read More
UK doctors allowed to prescribe medical cannabis from November
From November 1 specialist clinicians in the UK will be able to prescribe cannabis-derived medicinal products for the first time after a change in the law, the Home Office has confirmed.
Read More
GW Pharma’s Epidiolex nears US launch
GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified the cannabis-based medicine to the lowest restriction.
Read More
FDA advisors back approval of GW’s Epidiolex
As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Read More
GW’s cannabidiol gets EU orphan status for TS
GW Pharma’s cannabidiol (CBD) has been granted orphan drug designation by European regulators for the treatment of tuberous sclerosis (TS).
Read More
GW Pharma poised to file Epidiolex in the US
GW Pharmaceuticals is on the brink of filing its cannabis-derived therapy Epidiolex in the US as another late-stage study highlights the drug’s efficacy in treating Dravet Syndrome, a rare and severe type of epilepsy.
Read More
GW’s Epidiolex on track for LGS filing mid-year
GW Pharma’s Epidiolex has impressed again in a late-stage trial involving patients with the rare form of epilepsy Lennox-Gastaut Syndrome (LGS), significantly reducing the number of drop seizures experienced.
Read More
Orphan status for GW’s rare epilepsy drug
London, UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as a treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
Read More
GW Pharma unveils new financial head
GW Pharma has named Scott Giacobello as chief financial officer (CFO) of the group.
Read More
GW Pharma’s cannabinoid hits targets in epilepsy trial
GW Pharmaceuticals has unveiled yet more positive data from a late-stage programme testing its cannabinoid Epidiolex in rare epilepsies, pushing its stock up more than 16 percent.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
